Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:06:44.750Z.
Calculation as of: 2026-10-06T17:06:44.750Z.
Quote observation: 2026-10-06T17:05:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$410.64M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$410.81M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.54M
EBITDA Yield
N/A
TTM Avg
951.70%
3Y Avg
394.96%
5Y Avg
394.96%
Market Cap
$413.10M
EBITDA Yield
N/A
TTM Avg
6.82%
3Y Avg
6.82%
5Y Avg
6.82%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $410.64M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $410.81M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.37M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $409.04M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $408.54M | N/A | 951.70% | 394.96% | 394.96% |
| Myriad Genetics, Inc. (MYGN)vs › | $416.04M | N/A | 3.45% | 4.91% | 6.50% |
| Prothena Corporation plc (PRTA)vs › | $413.10M | N/A | 6.82% | 6.82% | 6.82% |
| Rezolute, Inc. (RZLT)vs › | $412.95M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $405.61M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $418.36M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
